Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine Cream USP, 2.5%/2.5% (USRLD: EMLA® Cream, 2.5%/2.5%).
Lidocaine and Prilocaine Cream USP is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anaesthesia. Lidocaine and Prilocaine cream will be produced at the Group's topical manufacturing site at Changodar, Ahmedabad.
Lidocaine and Prilocaine cream had annual sales of USD 22.05 mn in the United States (IQVIA MAT October 2024).
The group now has 412 approvals and has so far filed over 473* ANDAs since the commencement of the filing process in FY 2003-04.
Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 979.10 as compared to the previous close of Rs. 969.50. The total number of shares traded during the day was 11664 in over 1349 trades.
The stock hit an intraday high of Rs. 983.95 and intraday low of 968.90. The net turnover during the day was Rs. 11421483.00. |
